Hypoxia: A Double-Edged Sword in Cancer Therapy

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs

(2016) Roger M. Phillips   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance

(2016) Hiroshi Harada   JOURNAL OF RADIATION RESEARCH

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

(2015) Jessica D Sun et al.   CANCER BIOLOGY & THERAPY

Prolyl hydroxylase inhibitors act as agents to enhance the efficiency of cell therapy

(2015) Maryam Esfahani et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Progress toward overcoming hypoxia-induced resistance to solid tumor therapy

(2015) Mauricio Reginato et al.   Cancer Management and Research

Targeting hypoxia at the forefront of anticancer immune responses

(2015) Muhammad Zaeem Noman et al.   OncoImmunology

Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response

(2014) S R McKeown   BRITISH JOURNAL OF RADIOLOGY

Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment

(2014) Vinit Kumar et al.   IMMUNOLOGY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery

(2014) Anna K. Renfrew   Metallomics

Hypoxia-regulated microRNAs in human cancer

(2013) Guomin Shen et al.   ACTA PHARMACOLOGICA SINICA

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

(2013) Christopher P. Guise et al.   Chinese Journal of Cancer

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

(2013) Annika Foehrenbacher et al.   Frontiers in Oncology

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

(2012) Hiroshi Harada et al.   Nature Communications

Microenvironment and Radiation Therapy

(2012) Michio Yoshimura et al.   Biomed Research International

Introduction of hypoxia-targeting p53 fusion protein for the selective therapy of non-small cell lung cancer

(2011) Yu Zhao et al.   CANCER BIOLOGY & THERAPY

Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide

(2011) I. B. Barsoum et al.   CANCER RESEARCH

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

(2011) J. D. Sun et al.   CLINICAL CANCER RESEARCH

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

(2011) G. J. Weiss et al.   CLINICAL CANCER RESEARCH

Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways

(2011) Nadine Rohwer et al.   DRUG RESISTANCE UPDATES

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Macrophage Expression of Hypoxia-Inducible Factor-1  Suppresses T-Cell Function and Promotes Tumor Progression

(2010) A. L. Doedens et al.   CANCER RESEARCH

Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis

(2010) X. Lu et al.   CLINICAL CANCER RESEARCH

Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

(2010) William A Denny   Future Oncology

The remarkable yin and yang of tumour hypoxia

(2010) Martin Brown   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Hypoxia-specific gene expression for ischemic disease gene therapy

(2009) Hyun Ah Kim et al.   ADVANCED DRUG DELIVERY REVIEWS

Suppression of Hypoxia-Inducible Factor 2  Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells

(2009) A. M. Roberts et al.   CANCER RESEARCH

Role of hypoxia in the hallmarks of human cancer

(2009) Kai Ruan et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

(2009) S. Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

(2008) M. R. Albertella et al.   CLINICAL CANCER RESEARCH

Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile

(2008) Angela Rita Elia et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study

(2008) Katsuyuki Karasawa et al.   RADIOTHERAPY AND ONCOLOGY